Research ArticleExperimental Studies

Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model

GUANGWEI ZHU, MING ZHAO, QINGHONG HAN, YUYING TAN, YU SUN, MICHAEL BOUVET, SHREE RAM SINGH, JIANXIN YE and ROBERT M. HOFFMAN
Anticancer Research November 2019, 39 (11) 5999-6005; DOI: https://doi.org/10.21873/anticanres.13805

Abstract

Background/Aim: In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model. Materials and Methods: A patient CRC tumor previously established in nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice. Harvested tumor fragments were transplanted orthotopically in non-transgenic nude mice. Mice were randomized into three groups: Group 1 (G1), untreated-control; Group 2 (G2), OXA+5-FU; Group 3 (G3), TRAB+OXA+5-FU. Tumor width, length, and mouse body weight were measured twice a week. Results: Both treatment groups inhibited tumor growth compared to the untreated control group. The combination of TRAB, OXA and 5-FU was significantly more efficacious than OXA+5-FU and arrested tumor growth. No significant changes were observed in body-weight in any of the three groups. Conclusion: TRAB, OXA and 5-FU combination has clinical potential for this and other CRC patients.

Currently-available treatment strategies for colorectal cancer (CRC) mainly include surgical resection, radiotherapy and adjuvant chemotherapy. Oxaliplatinum (OXA)-based chemotherapy after surgical resection is one of the most frequently used therapeutic strategies (1). OXA combined with 5-fluorouracil (5-FU) has increased the survival rate in patients with CRC (2). However, a large proportion of patients with CRC receiving chemotherapy recur and develop chemo-resistant metastasis (3). Therefore, more effective therapies are needed for metastatic CRC.

To accomplish this goal, we have developed a patient-derived orthotopic xenograft (PDOX) nude mouse model for many tumor types (4-13). To test the response of various chemotherapies on individual CRC patients, we have also developed CRC PDOX nude-mouse models and orthotopic cell line (13-21).

Trabectedin (TRAB) has been used for treating many cancer types (22, 23). TRAB is effective against many tumors resistant to alkylating agents (24). However, there are few studies where it has been shown that TRAB is active in CRC. Stevens et al., (25) have reported that several colorectal cell lines are highly resistant to cisplatinum and sensitive to TRAB. Izbicka et al. (23) and Twelves et al. (26) have shown that CRC patients could benefit from TRAB. In the present study, we show that TRAB is efficacious on a CRC PDOX mouse model in combination with OXA+5-FU.

Figure 1.
Figure 1.

Establishment of a patient-derived orthotopic xenograft (PDOX) model and drug treatment schema. (A) Schematic illustration of the surgical orthotopic implantation (SOI) for establishment of imageable PDOX (iPDOX) models of human colorectal cancer. (B) Treatment regime and quantitative drug efficacy. Treatment protocol. G1: untreated control (n=7); G2: treated with OXA+5-FU (OXA 6 mg/kg+5-FU 50 mg/kg; i.p., weekly for 2 weeks); G3: treated with TRAB+OXA+5-FU (TRAB 0.15 mg/kg, i.v. and OXA 6 mg/kg+5-FU 50 mg/kg; i.p., weekly for 2 weeks). All treated mice were sacrificed on the endpoint day, and tumors were resected for further histological evaluation.

Materials and Methods

Mice. Athymic nu/nu nude mice 4- to 6-weeks and transgenic green fluorescence protein (GFP) expressing athymic nu/nu mice were obtained from AntiCancer Inc. (San Diego, CA, USA). All surgical procedures and imaging were performed in accordance with an AntiCancer Inc. Institutional Animal Care and Use Committee (IACUC)-protocol specifically approved for this study, and in accordance with the principles and procedures outlined in the National Institutes of Health Guidelines for the Care and Use of Animals under Assurance Number A3873-1 (11). Mouse housing, feeding, anesthesia and surgical procedures were performed as described in previous publications (11, 27). The mice were humanely sacrificed based our previous publication (27).

Patient-derived tumor. The primary tumor was previously obtained from a patient with CRC in the Division of Surgical Oncology, University of California, San Diego (UCSD). The patient did not receive any chemotherapy or radiotherapy prior to surgery. Fresh tumor tissues were obtained from the patient at surgery with informed patient consent and Institutional Review Board (IRB) approval. The CRC PDOX mouse model (iPDOX) was established using the surgical orthotopic implantation (SOI) technique, as previously reported (14).

Establishing the imageable CRC PDOX model. CRC samples were cut into 5 mm3 fragments and implanted subcutaneously in nude mice. The resulting CRC tumors grown in non-transgenic nude mice were harvested, cut into 5 mm3 fragments, and implanted subcutaneously in green fluorescence protein (GFP)-expressing transgenic nude mice. After two passages in GFP-expressing nude mice, tumors stably containing GFP-expressing stromal cells were harvested and cut into 5 mm3 fragments. After non-transgenic nude mice were anesthetized with a ketamine mixture, an approximately 1-cm skin incision was made at the middle of the abdomen. 8-0 nylon sutures were used to implant tumor fragments onto the cecum. Wounds were closed using 6-0 nylon sutures as described before (14). The schematic diagram to establish a CRC PDOX model is shown in Figure 1A.

Figure 2.
Figure 2.

Imaging of PDOX tumors treated with each drug, and quantitative efficacy of chemotherapy on the CRC PDOX model. Images of representative PDOX mouse models from each treatment group at the endpoint. Arrows indicate GFP-expression of tumor stromal cells. (A) Untreated control. (B) OXA+5-FU. (C) TRAB+ OXA+5-FU. The Fluor Vivo Imaging System was used (28). (D) Line graphs indicate relative tumor volume (ratio of tumor volume at each time point to volume at initiation of treatment) for each drug and control group. n=7 mice/group. *p<0.05; ***p<0.001.

Treatment study design. Six weeks after orthotopic implantation of CRC-GFP tumors, the abdomen of the PDOX mice was opened to observe tumor growth. The PDOX mice were randomized into 3 groups (7 mice/per treatment group) by measuring tumor size: Group 1 (G1), control group (no treatment); Group 2 (G2), OXA+5-FU (OXA 6 mg/kg; 5-FU 50 mg/kg; i.p., weekly for 2 weeks); Group 3 (G3), TRAB+ OXA+5-FU (0.15 mg/kg, i.v.; OXA 6 mg/kg; 5-FU 50 mg/kg; i.p., weekly for 2 weeks) (Figure 1B). Tumor length, width and mouse body weight were measured twice a week. Tumor volume was calculated by the following formula: tumor volume (mm3)=length (mm)×width (mm)×width (mm)×1/2. Data are presented as mean±SD. Mice were imaged with the Fluor Vivo Imaging System (INDEC Biosystem, Santa Clara, CA, USA) (28).

Histological analysis. Fresh tumor samples were fixed in 10% formalin and embedded in paraffin before sectioning and staining. Four-μm tissue sections were deparaffinized in xylene and rehydrated in an ethanol series. Hematoxylin and eosin (H&E) staining was carried out according to a standard protocol. Histological visualization was performed with a BHS system microscope and images were acquired with INFINITY ANALYZE software (Lumenera Corporation, Ottawa, Canada) (29).

Figure 3.
Figure 3.

Effect of drugs on mouse body weight. Bar graph shows body weight in each group at pre-treatment (A) and 2 weeks post-treatment (B). There were no significant differences between any group.

Figure 4.
Figure 4.

Histology of colorectal cancer PDOX mouse model in treated and untreated tumors. Hematoxylin and eosin (H&E)-stained sections of the (A) Untreated control group. (B) OXA+5-FU treated group, and (C) TRAB+OXA+5-FU treated group. Microscope magnification is 200×.

Statistical analysis. All statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, Inc. La Jolla, CA, USA). Data were analyzed by ANOVA with Tukey's post-hoc test when more than two groups were compared. The data were expressed as the mean±SD. A p-value of <0.05 was considered to be statistically significant.

Results

Drug efficacy. To test the efficacy of each drug in the CRC PDOX mouse models, six weeks following orthotopic implantation, mice with tumors were randomized into three groups to initiate treatment (Figure 1B). The tumor volumes at the endpoint of the experiment were: G1 untreated control, 514.8±20.3 mm3 (Figure 2A); G2 OXA+5-FU, 185.4±24.3 mm3 (Figure 2B); G3 TRAB+OXA+5-FU, 127±12 mm3 (Figure 2C). The control group (G1) tumors grew more than four times larger after 2 weeks compared to the time of the initial treatment (tumor-volume ratio= 4.65±1.48). In the OXA+5-FU group (G2), at the endpoint, there was significant inhibition in tumor growth compared to the control group (tumor-volume ratio=1.67±1.77, p<0.001). The TRAB+OXA +5-FU combination group (G3) arrested tumor growth (tumor-volume ratio=1.15±0.88, p<0.001, compared to the control) (Figure 2D). The TRAB+OXA+5-FU (G3) group resulted in a greater inhibition of tumor growth than the OXA+5-FU group (G2) (p<0.05) (Figure 2D).

Effect of drug treatment on body weight. There was no significant difference observed in body weight in all three groups (Figure 3A, B).

Tumor histology. Histologically, the un-treated control tumor mainly comprised viable cancer cells (Figure 4A). In the tumors treated with OXA+5-FU, cancer-cell density was lower than that of the control (Figure 4B, C). The strongest efficacy was observed with the combination of TRAB+OXA+5-FU. In this group, cancer cell density was the lowest among all three groups (Figure 4C).

Discussion

OXA+5-FU is first line treatment for CRC (30, 31). Although OXA combined with 5-FU showed a response in the majority of CRC cases, virtually all the responses are incomplete because patients have recurrences. In order to develop an effective curative strategy, the combination of TRAB+OXA+5-FU was tested to see whether it is efficacious in inhibiting the growth of a CRC PDOX mouse model. We found that the combination of TRAB+OXA+5-FU was more effective compared to the OXA+5-FU regimen.

TRAB has been previously shown to re-sensitize resistant cells in some tumors (32). TRAB has also been shown to be efficacious in sarcoma (33-36), recurrent ovarian cancer (37), metastatic breast cancer (38), juvenile myelomonocytic leukemia, and chronic myelomonocytic leukemia (39) and we found that TRAB was effective in PDOX models of sarcoma (40-43).

Although, some studies have shown that TRAB may be effective for CRC (23, 25, 26), no studies have examined the efficacy of the combination of TRAB+OXA+5-FU on CRC. In the present study, we showed that TRAB+OXA+5-FU was highly effective against a PDOX mouse model of CRC, suggesting the use of this combination in the clinic.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No.81702424 and 81872364), The Joint Funds for the Innovation of Science and Technology, Fujian Province(No.2017Y9092), The Fujian Provincial Health Department Young and Middle-aged Talents Training Project(No.2018-ZQN-46), The Project of Science and Technology Research Program in Fujian Province (No. 2016B044), The Fujian Provincial Natural Science Foundation (No.2018J05127), the National Clinical Key Specialty Construction Project (General Surgery) of China. This paper is dedicated to the memory of A.R. Moossa, MD, Sun Lee, MD, Professor Li Jiaxi, and Masaki Kitajima, MD.

Footnotes

  • Authors' Contributions

    GWZ, and J-XY designed the study, modified the figures and wrote draft manuscript; GWZ performed the experiments; MZ, QHH and YS gave help in the experiments; SRS and RMH revised the manuscript. All Authors approved the final manuscript.

  • Conflicts of Interest

    GWZ, YS and RMH are unpaid affiliates of Anticancer Inc. MZ and QH are employees of AntiCancer Inc. AntiCancer Inc. uses PDOX models for contract research. The authors declare no conflicts of interest regarding this study.

  • Received October 10, 2019.
  • Revision received October 21, 2019.
  • Accepted October 22, 2019.

References

  1. ↵
    1. Yang AD,
    2. Fan F,
    3. Camp ER,
    4. van Buren G,
    5. Liu W,
    6. Somcio R,
    7. Gray MJ,
    8. Cheng H,
    9. Hoff PM,
    10. Ellis LM
    : Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Can Res 12(14 Pt 1): 4147-4153, 2006. PMID: 16857785. DOI: 10.1158/1078-0432.CCR-06-0038
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Alberts SR,
    2. Horvath WL,
    3. Sternfeld WC,
    4. Goldberg RM,
    5. Mahoney MR,
    6. Dakhil SR,
    7. Levitt R,
    8. Rowland K,
    9. Nair S,
    10. Sargent DJ,
    11. Donohue JH
    : Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36): 9243-9249, 2005. PMID: 16230673. DOI: 10.1200/JCO.2005.07.740
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Goldberg RM,
    2. Sargent DJ,
    3. Morton RF,
    4. Fuchs CS,
    5. Ramanathan RK,
    6. Williamson SK,
    7. Findlay BP,
    8. Pitot HC,
    9. Alberts SR
    : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1): 23-30, 2004. PMID: 14665611. DOI: 10.1200/JCO.2004.09.046
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Hoffman RM
    : Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 15(8): 451-452, 2015. PMID: 26422835. DOI: 10.1038/nrc3972
    OpenUrlCrossRefPubMed
    1. Hiroshima Y,
    2. Maawy AA,
    3. Katz MH,
    4. Fleming JB,
    5. Bouvet M,
    6. Endo I,
    7. Hoffman RM
    : Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograft (PDOX) nude-mouse model of human pancreatic cancer. J Surg Oncol 111(3): 311-315, 2015. PMID: 25394368. DOI: 10.1002/jso.23816
    OpenUrlPubMed
    1. Hiroshima Y,
    2. Zhang Y,
    3. Zhang N,
    4. Maawy A,
    5. Mii S,
    6. Yamamoto M,
    7. Uehara F,
    8. Miwa S,
    9. Yano S,
    10. Murakami T,
    11. Momiyama M,
    12. Chishima T,
    13. Tanaka K,
    14. Ichikawa Y,
    15. Bouvet M,
    16. Murata T,
    17. Endo I,
    18. Hoffman RM
    : Establishment of a patient-derived orthotopic xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PloS One 10(2): e0117417, 2015. PMID: 25689852. DOI: 10.1371/journal.pone.0117417
    OpenUrlPubMed
    1. Hiroshima Y,
    2. Zhang Y,
    3. Zhang N,
    4. Uehara F,
    5. Maawy A,
    6. Murakami T,
    7. Mii S,
    8. Yamamoto M,
    9. Miwa S,
    10. Yano S,
    11. Momiyama M,
    12. Mori R,
    13. Matsuyama R,
    14. Chishima T,
    15. Tanaka K,
    16. Ichikawa Y,
    17. Bouvet M,
    18. Endo I,
    19. Hoffman RM
    : Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model. Anticancer Res 35(2): 697-701, 2015. PMID: 25667448.
    OpenUrlAbstract/FREE Full Text
    1. Hiroshima Y,
    2. Zhao M,
    3. Maawy A,
    4. Zhang Y,
    5. Katz MH,
    6. Fleming JB,
    7. Uehara F,
    8. Miwa S,
    9. Yano S,
    10. Momiyama M,
    11. Suetsugu A,
    12. Chishima T,
    13. Tanaka K,
    14. Bouvet M,
    15. Endo I,
    16. Hoffman RM
    : Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J Cell Biochem 115(7): 1254-1261, 2014. PMID: 24435915. DOI: 10.1002/jcb.24769
    OpenUrlPubMed
    1. Hoffman RM
    : Patient-derived orthotopic xenograft (PDOX) models of melanoma. Int J Mol Sci 18(9): E1875, 2017. PMID: 28858204. DOI: 10.3390/ijms18091875
    OpenUrl
    1. Murakami T,
    2. Murata T,
    3. Kawaguchi K,
    4. Kiyuna T,
    5. Igarashi K,
    6. Hwang HK,
    7. Hiroshima Y,
    8. Hozumi C,
    9. Komatsu S,
    10. Kikuchi T,
    11. Lwin TM,
    12. Delong JC,
    13. Miyake K,
    14. Zhang Y,
    15. Tanaka K,
    16. Bouvet M,
    17. Endo I,
    18. Hoffman RM
    : Cervical cancer patient-derived orthotopic xenograft (PDOX) is sensitive to cisplatinum and resistant to nab-paclitaxel. Cell Cycle 237(1): 61-65, 2017. PMID: 28011474. DOI: 10.21873/anticanres.11289
    OpenUrl
  11. ↵
    1. Kawaguchi K,
    2. Igarashi K,
    3. Murakami T,
    4. Kiyuna T,
    5. Nelson SD,
    6. Dry SM,
    7. Li Y,
    8. Russell TA,
    9. Singh AS,
    10. Chmielowski B,
    11. Unno M,
    12. Eilber FC,
    13. Hoffman RM
    : Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. Cell Cycle 16(11): 1063-1069, 2017. PMID: 28426279. DOI: 10.1080/15384101.2017.1314406
    OpenUrl
    1. Murakami T,
    2. Singh AS,
    3. Kiyuna T,
    4. Dry SM,
    5. Li Y,
    6. James AW,
    7. Igarashi K,
    8. Kawaguchi K,
    9. DeLong JC,
    10. Zhang Y,
    11. Hiroshima Y,
    12. Russell T,
    13. Eckardt MA,
    14. Yanagawa J,
    15. Federman N,
    16. Matsuyama R,
    17. Chishima T,
    18. Tanaka K,
    19. Bouvet M,
    20. Endo I,
    21. Eilber FC,
    22. Hoffman RM
    : Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 7(30): 47556-47564, 2016. PMID: 27286459. DOI: 10.18632/oncotarget.9879
    OpenUrl
  13. ↵
    1. Hiroshima Y,
    2. Maawy A,
    3. Metildi CA,
    4. Zhang Y,
    5. Uehara F,
    6. Miwa S,
    7. Yano S,
    8. Sato S,
    9. Murakami T,
    10. Momiyama M,
    11. Chishima T,
    12. Tanaka K,
    13. Bouvet M,
    14. Endo I,
    15. Hoffman RM
    : Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system. J Laparoendosc Adv Surg Tech A 24(4): 241-247, 2014. PMID: 24494971. DOI: 10.1089/lap.2013.0418
    OpenUrlPubMed
  14. ↵
    1. Fu XY,
    2. Besterman JM,
    3. Monosov A,
    4. Hoffman RM
    : Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 88: 9345-9349, 1991. PMID: 1924398. DOI: 10.1073/pnas.88.20.9345
    OpenUrlAbstract/FREE Full Text
    1. Bhattacharya A,
    2. Turowski SG,
    3. San Martin ID,
    4. Rajput A,
    5. Rustum YM,
    6. Hoffman RM,
    7. Seshadri M
    : Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Res 31(2): 387-393, 2011. PMID: 21378316.
    OpenUrlAbstract/FREE Full Text
    1. Ishihara Y,
    2. Matsunaga K,
    3. Iijima H,
    4. Hasegawa G,
    5. Suzuki T,
    6. Sato A,
    7. Kobayashi T,
    8. Yang M,
    9. Hoffman RM
    : The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer. Anticancer Res 30(2): 403-408, 2010. PMID: 20332446.
    OpenUrlAbstract/FREE Full Text
    1. Ji Y,
    2. Hayashi K,
    3. Amoh Y,
    4. Tsuji K,
    5. Yamauchi K,
    6. Yamamoto N,
    7. Tsuchiya H,
    8. Tomita K,
    9. Bouvet M,
    10. Hoffman RM
    : The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 27(2): 713-718, 2007. PMID: 17465193.
    OpenUrlAbstract/FREE Full Text
    1. Ma H,
    2. Das T,
    3. Pereira S,
    4. Yang Z,
    5. Zhao M,
    6. Mukerji P,
    7. Hoffman RM
    : Efficacy of dietary antioxidants combined with a chemotherapeutic agent on human colon cancer progression in a fluorescent orthotopic mouse model. Anticancer Res 29(7): 2421-2426, 2009. PMID: 19596909.
    OpenUrlAbstract/FREE Full Text
    1. Park JH,
    2. Zhao M,
    3. Oshiro H,
    4. Miyake K,
    5. Higuchi T,
    6. Reynoso J,
    7. Razmjooei S,
    8. Bouvet M,
    9. Clary B,
    10. Zhang Z,
    11. Sugisawa N,
    12. Yamamoto J,
    13. Singh SR,
    14. Hoffman RM
    : Peritoneal metastases in a patient-derived orthotopic xenograft (PDOX) model of colon cancer imaged non-invasively via red fluorescent protein labeled stromal cells. Anticancer Res 39(7): 3463-3467, 2019. PMID: 31262870. DOI: 10.21873/anticanres.13492
    OpenUrlAbstract/FREE Full Text
    1. Yoon SN,
    2. Park JH,
    3. Lwin TM,
    4. Miyake K,
    5. Singh SR,
    6. Hoffman RM,
    7. Bouvet M
    : Tumor-sealing surgical orthotopic implantation of human colon cancer in nude mice induces clinically-relevant metastases without early peritoneal carcinomatosis. Anticancer Res 39(8): 4065-4071, 2019. PMID: 31366489. DOI: 10.21873/anticanres.13563
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Park JH,
    2. Zhao M,
    3. Han Q,
    4. Sun Y,
    5. Higuchi T,
    6. Sugisawa N,
    7. Yamamoto J,
    8. Singh SR,
    9. Clary B,
    10. Bouvet M,
    11. Hoffman RM
    : Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun 518(2): 306-310, 2019. PMID: 31421825. DOI: 10.1016/j.bbrc.2019.08.051
    OpenUrl
  22. ↵
    1. H Hendriks HR,
    2. Fiebig HH,
    3. Giavazzi R,
    4. Langdon SP,
    5. Jimeno JM,
    6. Faircloth GT
    : High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10(10): 1233-1240, 1999. PMID: 10586342. DOI: 10.1023/a:1008364727071
    OpenUrlCrossRefPubMed
  23. ↵
    1. Izbicka E,
    2. Lawrence R,
    3. Raymond E,
    4. Eckhardt G,
    5. Faircloth G,
    6. Jimeno J,
    7. Clark G,
    8. Von Hoff DD
    : In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9(9): 981-987, 1998. PMID: 9818072. DOI: 10.1023/A:1008224322396
    OpenUrlCrossRefPubMed
  24. ↵
    1. Carter NJ,
    2. Keam SJ
    : Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67(15): 2257-2276, 2007. PMID: 17927287. DOI: 10.2165/00003495-200767150-00009
    OpenUrlCrossRefPubMed
  25. ↵
    1. Stevens EV,
    2. Nishizuka S,
    3. Antony S,
    4. Reimers M,
    5. Varma S,
    6. Young L,
    7. Munson PJ,
    8. Weinstein JN,
    9. Kohn EC,
    10. Pommier Y
    : Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 7(1): 10-18, 2008. PMID: 18187810. DOI: 10.1158/1535-7163.MCT-07-0192
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Twelves C,
    2. Hoekman K,
    3. Bowman A,
    4. Vermorken JB,
    5. Anthoney A,
    6. Smyth J,
    7. van Kesteren C,
    8. Beijnen JH,
    9. Uiters J,
    10. Wanders J,
    11. Gomez J,
    12. Guzmán C,
    13. Jimeno J,
    14. Hanauske A
    : Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 39(13): 1842-1851, 2003. PMID: 12932661. DOI: 10.1016/s0959-8049(03)00458-1
    OpenUrlCrossRefPubMed
  27. ↵
    1. Igarashi K,
    2. Kawaguchi K,
    3. Kiyuna T,
    4. Miyake K,
    5. Miyake M,
    6. Li Y,
    7. Nelson SD,
    8. Dry SM,
    9. Singh AS,
    10. Elliott IA,
    11. Russell TA,
    12. Eckardt MA,
    13. Yamamoto N,
    14. Hayashi K,
    15. Kimura H,
    16. Miwa S,
    17. Tsuchiya H,
    18. Eilber FC,
    19. Hoffman RM
    : Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy. J Cell Biochem 119(8): 6598-6603, 2018. PMID: 29737543. DOI: 10.1002/jcb.26792
    OpenUrl
  28. ↵
    1. Oshiro H,
    2. Kiyuna T,
    3. Tome Y,
    4. Miyake K,
    5. Kawaguchi K,
    6. Higuchi T,
    7. Miyake M,
    8. Zhang Z,
    9. Razmjooei S,
    10. Barangi M,
    11. Wangsiricharoen S,
    12. Nelson SD,
    13. Li Y,
    14. Bouvet M,
    15. Singh SR,
    16. Kanaya F,
    17. Hoffman RM
    : Detection of metastasis in a patient-derived orthotopic xenograft (PDOX) model of undifferentiated pleomorphic sarcoma with red fluorescent protein. Anticancer Res 39(1): 81-85, 2019. PMID: 30591443. DOI: 10.21873/anticanres.13082
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Igarashi K,
    2. Kawaguchi K,
    3. Murakami T,
    4. Kiyuna T,
    5. Miyake K,
    6. Singh AS,
    7. Nelson SD,
    8. Dry SM,
    9. Li Y,
    10. Yamamoto N,
    11. Hayashi K,
    12. Kimura H,
    13. Miwa S,
    14. Tsuchiya H,
    15. Eilber FC,
    16. Hoffman RM
    : High efficacy of pazopanib on an undifferentiated spindle-cell sarcoma resistant to first-line therapy is identified with a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Cell Biochem 118(9): 2739-2743, 2017. PMID: 28176365. DOI: 10.1002/jcb.25923
    OpenUrl
  30. ↵
    1. Nautiyal J,
    2. Kanwar SS,
    3. Yu Y,
    4. Majumdar AP
    : Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal 6: 7, 2011. PMID: 21774804. DOI: 10.1186/1750-2187-6-7
    OpenUrlCrossRefPubMed
  31. ↵
    1. Li P,
    2. Zhang X,
    3. Wang H,
    4. Wang L,
    5. Liu T,
    6. Du L,
    7. Yang Y,
    8. Wang C
    : MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther 16(4): 739-751, 2017. PMID: 28069878. DOI: 10.1158/1535-7163.MCT-16-0591
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Loria R,
    2. Laquintana V,
    3. Bon G,
    4. Trisciuoglio D,
    5. Frapolli R,
    6. Covello R,
    7. Amoreo CA,
    8. Ferraresi V,
    9. Zoccali C,
    10. Novello M,
    11. Del Bufalo D,
    12. Milella M,
    13. Biagini R,
    14. D'Incalci M,
    15. Falcioni R
    : HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene 37(45): 5926-5938, 2018. PMID: 29980789. DOI: 10.1038/s41388-018-0394-x
    OpenUrl
  33. ↵
    1. Gronchi A,
    2. Bui BN,
    3. Bonvalot S,
    4. Pilotti S,
    5. Ferrari S,
    6. Hohenberger P,
    7. Hohl RJ,
    8. Demetri GD,
    9. Le Cesne A,
    10. Lardelli P,
    11. Pérez I,
    12. Nieto A,
    13. Tercero JC,
    14. Alfaro V,
    15. Tamborini E,
    16. Blay JY
    : Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 23(3): 771-776, 2012. PMID: 21642514. DOI: 10.1093/annonc/mdr265
    OpenUrlCrossRefPubMed
    1. De Sanctis R,
    2. Marrari A,
    3. Marchetti S,
    4. Mussi C,
    5. Balzarini L,
    6. Lutman FR,
    7. Daolio P,
    8. Bastoni S,
    9. Bertuzzi AF,
    10. Quagliuolo V,
    11. Santoro A
    : Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. Drug Des Devel Ther 9: 5785-5791, 2015. PMID: 26604682. DOI: 10.2147/DDDT. S92395
    OpenUrl
    1. Bui-Nguyen B,
    2. Butrynski JE,
    3. Penel N,
    4. Blay JY,
    5. Isambert N,
    6. Milhem M,
    7. Kerst JM,
    8. Reyners AK,
    9. Litière S,
    10. Marréaud S,
    11. Collin F,
    12. van der Graaf WT
    : European organisation for research and treatment of cancer soft tissue and bone sarcoma group (EORTC/STBSG) and the sarcoma alliance for research through collaboration (SARC): a phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer 51(10): 1312-1320, 2015. PMID: 25912752. DOI: 10.1016/j.ejca.2015.03.023
    OpenUrl
  36. ↵
    1. Takahashi M,
    2. Takahashi S,
    3. Araki N,
    4. Sugiura H,
    5. Ueda T,
    6. Yonemoto T,
    7. Morioka H,
    8. Hiraga H,
    9. Hiruma T,
    10. Kunisada T,
    11. Matsumine A,
    12. Shimura M,
    13. Kawai A
    : Efficacy of trabectedin in patients with advanced translocation-related sarcomas: pooled analysis of two phase II studies. Oncologist 22(8): 979-988, 2017. PMID: 28526720. DOI: 10.1634/theoncologist.2016-0064
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Adam JP,
    2. Boumedien F,
    3. Letarte N,
    4. Provencher D
    : Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 147(1): 47-53, 2017. PMID: 28751117. DOI: 10.1016/j.ygyno.2017.07.123
    OpenUrl
  38. ↵
    1. Ghouadni A,
    2. Delaloge S,
    3. Lardelli P,
    4. Kahatt C,
    5. Byrski T,
    6. Blum JL,
    7. Gonçalves A,
    8. Campone M,
    9. Nieto A,
    10. Alfaro V,
    11. Cullell-Young M,
    12. Lubinski J
    : Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial. Breast 34: 18-23, 2017. PMID: 28467918. DOI: 10.1016/j.breast.2017.04.006
    OpenUrl
  39. ↵
    1. Romano M,
    2. Della Porta MG,
    3. Gallì A,
    4. Panini N,
    5. Licandro SA,
    6. Bello E,
    7. Craparotta I,
    8. Rosti V,
    9. Bonetti E,
    10. Tancredi R,
    11. Rossi M,
    12. Mannarino L,
    13. Marchini S,
    14. Porcu L,
    15. Galmarini CM,
    16. Zambelli A,
    17. Zecca M,
    18. Locatelli F,
    19. Cazzola M,
    20. Biondi A,
    21. Rambaldi A,
    22. Allavena P,
    23. Erba E,
    24. D'Incalci M
    : Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. Br J Cancer 116(3): 335-343, 2017. PMID: 28072764. DOI: 10.1038/bjc.2016.424
    OpenUrl
  40. ↵
    1. Higuchi T,
    2. Miyake K,
    3. Oshiro H,
    4. Sugisawa N,
    5. Yamamoto N,
    6. Hayashi K,
    7. Kimura H,
    8. Miwa S,
    9. Igarashi K,
    10. Chawla SP,
    11. Bouvet M,
    12. Singh SR,
    13. Tsuchiya H,
    14. Hoffman RM
    : Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. Biochem Biophys Res Commun 513: 326-331, 2019. PMID: 30955860. DOI: 10.1016/j.bbrc.2019.03.191
    OpenUrl
    1. Zhang Z,
    2. Hu K,
    3. Kiyuna T,
    4. Miyake K,
    5. Kawaguchi K,
    6. Igarashi K,
    7. Nelson SD,
    8. Li Y,
    9. Singh SR,
    10. Hoffman RM
    : A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. Pharmacol Res 142: 169-175, 2019. PMID: 30807865. DOI: 10.1016/j.phrs.2019.02.021
    OpenUrl
    1. Kiyuna T,
    2. Tome Y,
    3. Murakami T,
    4. Kawaguchi K,
    5. Igarashi K,
    6. Miyake K,
    7. Miyake M,
    8. Li Y,
    9. Nelson SD,
    10. Dry SM,
    11. Singh AS,
    12. Russell TA,
    13. Elliott I,
    14. Singh SR,
    15. Kanaya F,
    16. Eilber FC,
    17. Hoffman RM
    : Trabectedin arrests a doxorubicin resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. BMC Cancer 18(1): 840, 2018. PMID: 30126369. DOI: 10.1186/s12885-018-4703-0
    OpenUrl
  43. ↵
    1. Igarashi K,
    2. Murakami T,
    3. Kawaguchi K,
    4. Kiyuna T,
    5. Miyake K,
    6. Zhang Y,
    7. Nelson SD,
    8. Dry SM,
    9. Li Y,
    10. Yanagawa J,
    11. Russell TA,
    12. Singh AS,
    13. Tsuchiya H,
    14. Elliott I,
    15. Eilber FC,
    16. Hoffman RM
    : A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. Oncotarget 8: 62111-62119, 2017. PMID: 28977930. DOI: 10.18632/oncotarget.19095
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model
GUANGWEI ZHU, MING ZHAO, QINGHONG HAN, YUYING TAN, YU SUN, MICHAEL BOUVET, SHREE RAM SINGH, JIANXIN YE, ROBERT M. HOFFMAN
Anticancer Research Nov 2019, 39 (11) 5999-6005; DOI: 10.21873/anticanres.13805
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords